Terns Pharmaceuticals, Inc. (TERN) Q1 2023 Earnings Results

Terns Pharmaceutical Misses on EPS — Stock Down 6.24%

Terns Pharmaceutical's earnings report indicates ongoing challenges, particularly reflected in the missed EPS target. The stock dropped 6.24% in response, suggesting investor concern over the company's current performance and lack of guidance. Without clear direction from management, investors may remain cautious in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.31	N/A	-10.71%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management acknowledged the difficulties faced in the current environment. They emphasized a focus on long-term strategies despite short-term setbacks.

Management expressed concerns about ongoing challenges in the market.

They highlighted the need for strategic adjustments moving forward.

Terns Pharmaceutical Misses on EPS — Stock Down 6.24%

Key numbers

Management commentary

Terns Pharmaceuticals, Inc.

More earnings this week

Terns Pharmaceutical Misses on EPS — Stock Down 6.24%

Key numbers

Management commentary